Nimovo500 mg+20 mg

Nimovo is a fixed-dose combination of an NSAID (naproxen sodium) and a proton pump inhibitor (esomeprazole), used as follows:

Established / FDA-approved use

• Relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adult patients who require ongoing NSAID therapy and who are judged to be at risk of developing NSAID-associated gastric ulcers.

Important limitation

Nimovo is a delayed-release combination and is not recommended for the initial treatment of acute pain because the naproxen component is absorbed more slowly than with immediate-release naproxen alone. It is intended for patients who need long-term, regular NSAID dosing, not for as-needed short-term pain relief.

Nimovo does not treat the underlying disease (e.g., osteoarthritis or rheumatoid arthritis) but relieves pain, stiffness, and inflammation associated with it; the esomeprazole component is included specifically to reduce (not eliminate) the risk of NSAID-induced gastric ulcers, not to treat unrelated acid-reflux conditions on its own.

Each delayed-release tablet of Naproxen Sodium + Esomeprazole contains naproxen sodium combined with esomeprazole magnesium, formulated as a bilayer/core tablet: an immediate-release esomeprazole layer surrounding an enteric-coated naproxen core. This design allows esomeprazole to be released first to raise gastric pH, followed by release of naproxen once the tablet reaches the small intestine.

Commonly available strengths (as marketed in Bangladesh and internationally) are naproxen 375 mg + esomeprazole 20 mg, and naproxen 500 mg + esomeprazole 20 mg, per tablet.

Nimovo is an oral, fixed-dose combination medicine that pairs a non-steroidal anti-inflammatory drug (NSAID) with a proton pump inhibitor (PPI). Naproxen sodium provides analgesic, anti-inflammatory, and antipyretic effects by inhibiting cyclo-oxygenase (COX) enzymes, while esomeprazole reduces gastric acid secretion, lowering the risk of NSAID-associated gastric ulcers that can occur with long-term NSAID use.

Nimovo is supplied as a delayed-release tablet designed so that esomeprazole is released promptly in the stomach while naproxen is released later in the small intestine, once gastric acid has already been suppressed. It is intended for patients with chronic musculoskeletal pain/inflammation who need continued NSAID treatment and who have an increased risk of developing NSAID-related gastric ulcers.

Nimovo belongs to the therapeutic class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) combined with a Proton Pump Inhibitor (PPI) — specifically a gastroprotective NSAID combination product.

Naproxen Sodium + Esomeprazole combines two active components with complementary mechanisms:

• Naproxen (NSAID component): Naproxen non-selectively and reversibly inhibits cyclo-oxygenase-1 and -2 (COX-1 and COX-2) enzymes, reducing the synthesis of prostaglandins that mediate pain, inflammation, and fever. This produces analgesic, anti-inflammatory, and antipyretic effects, but also reduces the protective prostaglandins in the gastric mucosa, which is why gastric ulceration is a known risk of NSAID therapy.
• Esomeprazole (PPI component): Esomeprazole, the S-isomer of omeprazole, is a proton pump inhibitor that irreversibly binds to and inhibits the H+/K+-ATPase ("proton pump") in gastric parietal cells, suppressing both basal and stimulated gastric acid secretion. In Naproxen Sodium + Esomeprazole, the esomeprazole component is included specifically to reduce the risk of upper gastrointestinal ulcers associated with the naproxen component, not as a standalone acid-reflux treatment.

Pharmacokinetically, the tablet is engineered so esomeprazole is released immediately in the stomach (raising gastric pH before naproxen is exposed to the stomach), while the naproxen core is enteric-coated and releases only once the tablet reaches the higher pH of the small intestine, which delays naproxen absorption compared with immediate-release naproxen.

Take Nimovo tablets whole with a glass of water at least 30 minutes before a meal. Do not split, crush, or chew the tablet — doing so can destroy the delayed-release coating that protects the naproxen core and allows esomeprazole to act first. Nimovo is meant to be taken on a regular schedule, not as an as-needed medicine for sudden pain.

Nimovo can interact with several other medicines. Clinically significant interactions include:

• Anticoagulants (e.g., warfarin) and antiplatelet agents: Increased risk of serious gastrointestinal bleeding when combined with the naproxen component of Nimovo.
• Low-dose aspirin: Concomitant use with Nimovo increases the risk of serious gastrointestinal events compared with naproxen alone, although low-dose aspirin for cardioprotection is sometimes continued under medical supervision.
• ACE inhibitors, angiotensin receptor blockers (ARBs), and diuretics: The naproxen component may reduce the antihypertensive/diuretic effect and, in combination with these agents (especially in volume-depleted or elderly patients), increase the risk of acute kidney injury.
• Lithium: Naproxen can reduce renal clearance of lithium, raising lithium blood levels and the risk of toxicity; monitor lithium levels if co-administered with Nimovo.
• Methotrexate: Naproxen may reduce renal clearance of methotrexate, increasing the risk of methotrexate toxicity, particularly with higher methotrexate doses.
• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: Combination with the naproxen component further increases the risk of gastrointestinal bleeding.
• Cyclosporine and tacrolimus: Concurrent NSAID use may increase the nephrotoxic potential of these agents.
• Clopidogrel: Esomeprazole can inhibit CYP2C19-mediated activation of clopidogrel, potentially reducing its antiplatelet effect; concomitant use is generally discouraged unless no suitable alternative exists.
• Drugs dependent on gastric pH for absorption (e.g., ketoconazole, iron salts, certain HIV protease inhibitors, digoxin): The esomeprazole component raises gastric pH and can alter absorption of these drugs; digoxin levels should be monitored.
• CYP2C19 inducers/inhibitors (e.g., rifampin, St. John's Wort, voriconazole): May respectively decrease or increase esomeprazole plasma concentrations.
• Corticosteroids: Increase the risk of gastrointestinal ulceration/bleeding when used with the naproxen component of Nimovo.

Always inform your physician or pharmacist about all medicines, supplements, and herbal products being used before starting Nimovo.

Side effects of Nimovo arise from both the naproxen and esomeprazole components.

Common side effects

• Dyspepsia (indigestion), erosive gastritis/gastritis, heartburn
• Nausea, diarrhea, upper abdominal pain, constipation
• Headache
• Peripheral edema (fluid retention/swelling)
• Upper respiratory tract infection symptoms

Serious side effects (seek prompt medical attention)

• Signs of gastrointestinal bleeding, ulceration, or perforation (e.g., black or bloody stools, vomiting blood, severe stomach pain) — see Precautions and Warnings.
• Signs of a cardiovascular event such as chest pain, shortness of breath, weakness on one side of the body, or slurred speech (possible heart attack or stroke).
• Signs of a severe allergic/anaphylactoid reaction (swelling of the face/throat, difficulty breathing, severe rash).
• Severe skin reactions (blistering, peeling skin — possible Stevens-Johnson syndrome or toxic epidermal necrolysis).
• Signs of liver problems (yellowing of skin/eyes, dark urine, unusual fatigue).
• Signs of kidney problems (decreased urination, swelling, unusual tiredness).
• Low magnesium symptoms with long-term use (muscle spasms, irregular heartbeat, seizures).
• New or worsening high blood pressure, or worsening heart failure (swelling, sudden weight gain, shortness of breath).

Pregnancy: Nimovo should be avoided during pregnancy unless clearly necessary, and it is contraindicated in the third trimester because NSAIDs at around 20 weeks gestation or later can cause fetal renal dysfunction leading to low amniotic fluid, and, if used at or after 30 weeks, can cause premature closure of the fetal ductus arteriosus. Use earlier in pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close medical supervision.

Lactation: Naproxen is excreted in low quantities into human breast milk; because of the potential for serious adverse effects (including gastrointestinal bleeding) in a nursing infant, Nimovo should generally be avoided during breastfeeding unless a physician determines the benefit outweighs the risk, in which case the infant should be monitored closely.

Fertility: NSAIDs, including the naproxen component of Nimovo, have been associated with reversible female infertility; consider discontinuation in women having difficulty conceiving.

Always consult a physician before using Nimovo during pregnancy or breastfeeding.

Cardiovascular risk

NSAIDs, including the naproxen component of Nimovo, can increase the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and in patients with existing cardiovascular disease or risk factors. Nimovo is contraindicated for perioperative pain in CABG surgery and should be used with caution in patients with cardiovascular disease.

Gastrointestinal risk

NSAIDs, including Nimovo, can cause serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time and without warning symptoms, and can be fatal, particularly in the elderly. While the esomeprazole component of Nimovo reduces this risk compared with naproxen alone, it does not eliminate it. Patients with a prior history of peptic ulcer disease or GI bleeding, and those taking corticosteroids, anticoagulants, other NSAIDs, or SSRIs concurrently, are at greater risk.

Renal effects

Long-term NSAID use can cause renal papillary necrosis and other renal injury; patients with pre-existing renal impairment, heart failure, liver dysfunction, or volume depletion, and elderly patients, are at greatest risk. Nimovo is not recommended in moderate-to-severe renal impairment.

Hepatic effects

Borderline elevations of liver enzymes may occur; discontinue Nimovo if signs/symptoms of liver dysfunction develop or if abnormal liver tests persist or worsen.

Hypertension and fluid retention

Nimovo can cause new-onset hypertension or worsening of pre-existing hypertension, and fluid retention/edema; blood pressure should be monitored, and caution is warranted in patients with heart failure.

Long-term PPI-related risks

The esomeprazole component of Nimovo, when used long-term (generally more than one year), has been associated with an increased risk of bone fracture (hip, wrist, spine) and hypomagnesemia (which can cause muscle spasm, arrhythmia, or seizures); calcium/magnesium status may need periodic monitoring with prolonged use.

Other precautions

• Anaphylactoid reactions and serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported with NSAIDs; discontinue Nimovo at the first sign of skin rash or hypersensitivity.
• Use with caution in patients with pre-existing asthma, as NSAID-sensitive asthma can be exacerbated.
• Nimovo may mask signs of underlying infection due to its anti-inflammatory/antipyretic effect.
• Use the lowest effective dose for the shortest duration consistent with the treatment goals.

Overdose of Nimovo may cause symptoms related to either component. Naproxen overdose can cause lethargy, drowsiness, dizziness, nausea, vomiting, epigastric pain, gastrointestinal bleeding, and, in more severe cases, hypertension, acute kidney injury, or (rarely) seizures or coma. Esomeprazole overdose has generally produced only mild, transient symptoms, though data on very large overdoses are limited.

There is no specific antidote for Nimovo overdose. If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and symptomatic and should be provided under professional medical supervision (e.g., at a hospital); do not attempt to self-treat a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Elderly patients have a higher unbound fraction of naproxen and are generally more susceptible to NSAID-related gastrointestinal, cardiovascular, and renal adverse effects; use the lowest effective dose of Nimovo and monitor closely.
• Renal impairment: Nimovo is not recommended in patients with moderate-to-severe renal impairment (creatinine clearance under 30 mL/min); use with caution and close monitoring in mild impairment.
• Hepatic impairment: Use the lowest effective dose with caution in mild-to-moderate hepatic impairment; avoid Nimovo in patients with severe hepatic impairment.
• Pediatric patients: Nimovo may be used in adolescents 12 years and older at weight-based doses (see Dosage and Administration); safety and efficacy have not been established in children under 12 years (see Pediatric Uses).
• Cardiovascular disease/hypertension: Use with caution; monitor blood pressure and for signs of fluid retention or heart failure (see Precautions and Warnings).

Nimovo should be used at the lowest effective dose for the shortest duration consistent with the individual patient's treatment goals, because both gastrointestinal and cardiovascular risks may increase with longer duration of use. For chronic conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, treatment may need to continue long-term; in such cases, the need for continued therapy, the dose, and the patient's tolerance should be reassessed periodically by the prescribing physician. Long-term use (generally beyond one year) of the esomeprazole component also warrants periodic monitoring for bone and magnesium-related effects (see Precautions and Warnings).

Nonsteroidal Anti-Inflammatory Drug (NSAID) in fixed-dose combination with a Proton Pump Inhibitor (PPI) — a gastroprotective NSAID combination.

Naproxen Sodium + Esomeprazole works through the combined action of its two components:

• Naproxen non-selectively inhibits cyclo-oxygenase (COX-1 and COX-2), decreasing the production of prostaglandins responsible for pain, inflammation, and fever, thereby producing analgesic, anti-inflammatory, and antipyretic effects.
• Esomeprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system in gastric parietal cells, suppressing gastric acid secretion. This raises intragastric pH, which is intended to reduce the risk of upper gastrointestinal ulcers that can otherwise be caused by the naproxen component.

The tablet is formulated so that esomeprazole is released first in the stomach, ahead of naproxen, which is enteric-coated and released only in the small intestine — this sequencing is central to how Naproxen Sodium + Esomeprazole is designed to work.

Category C (use before 30 weeks of gestation only if clearly needed); Category D (at 30 weeks of gestation and later — avoid use).

Nimovo may be used in adolescents 12 years of age and older, dosed according to body weight: adolescents weighing 50 kg or more may receive the same dose as adults; those weighing 38 kg to less than 50 kg should receive the naproxen 375 mg/esomeprazole 20 mg tablet twice daily.

The safety and effectiveness of Nimovo have not been established in children younger than 12 years of age, and it should not be used in this age group outside of these established parameters.